1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

OPKO Health

Discussion in 'OPKO Health' started by anonymous, Aug 20, 2019 at 4:23 PM.

  1. anonymous

    anonymous Guest

    anyone work for this company? Would love some honest feedback on culture, how rayaldee is doing, are reps making bonus, is pulling through this drug a nightmare or does it go through on a P/A? Do Nephs and Endos want to write this drug? Or do they prefer a generic calcitriol? Thanks!